Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03022032 · ClinicalTrials.gov registry record · NA
The HOPE Trial and the SMART Study
A NA study of Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT03022032: Completed NA study of Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.
NCT03022032 is a NA study of Gynecologic Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 102 participants, below the 763-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03022032, a NA study of Gynecologic Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is evaluating a new smartphone application named the "Helping Our Patients Excel (HOPE)" app with a Fitbit device. The SMART Study is a sub-study of the HOPE Trial. Both studies evaluate an almost identical intervention using a Fitbit device and smartphone app(s) with the goal of improving quality-of-life for women with gynecologic cancers.
Primary Outcome
This outcome was limited to the HOPE pre-pilot, consisting of 10 patients. This open pilot aimed to identify patient preference of Fitbit Zip or Fitbit Charge 2 and whether this study was burdensome. This outcome informed appropriate study procedures before launching to a larger study with four arms across multiple sites. Feasibility defined as (1) greater than or equal to 60% enrollment rate among eligible patients approached, (2) greater than or equal to 70% adherence to daily smartphone surv
Conditions Studied
Interventions
- OTHER Standard of Care
- DEVICE Fitbit Zip
- OTHER HOPE App
- DEVICE Fitbit Charge 2
- OTHER SMART Study Intervention
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2020-09-02 |
| Phase | NA |
What the finished NCT03022032 record still lists
NCT03022032 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 763-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Gynecologic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Standard of Care is the first listed.
NCT03022032 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03022032 about?
NCT03022032 is a clinical study titled "The HOPE Trial and the SMART Study". This research study is evaluating a new smartphone application named the "Helping Our Patients Excel (HOPE)" app with a Fitbit device. The SMART Study is a sub-study of the HOPE Trial. Both studies evaluate an almost identical intervention using a Fitbit device and smartphone app(s) with the goal of...
What is the current status of trial NCT03022032?
This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2017-04-12. Estimated completion is 2020-09-02.
What conditions does trial NCT03022032 study?
This clinical trial studies the following conditions: Gynecologic Cancer.
What interventions are being tested in trial NCT03022032?
The interventions under investigation include: Standard of Care (OTHER), Fitbit Zip (DEVICE), HOPE App (OTHER), Fitbit Charge 2 (DEVICE), SMART Study Intervention (OTHER).
Who is sponsoring clinical trial NCT03022032?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03022032 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03022032's enrollment target sits among peer trials
102 18th of 55 higher than 37 of 55 other Gynecologic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Activity Coaching During Pelvic Radiation Therapy
RECRUITING · NA
-
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI